Development of a real-time reverse transcription polymerase chain reaction assay for c-myc expression that allows the identification of a subset of c-myc+ diffuse large B-cell lymphoma

Laboratory Investigation

Volumn 83, Issue 2, 2003, Pages 143-152

  Sáez, Ana Isabel ^a   Artiga, María Jesús ^a   Romero, Cristina ^a   Rodríguez, Sandra ^a   Cigudosa, Juan Cruz ^a   Pérez Rosado, Alberto ^a   Fernández, Isabel ^a   Sánchez Beato, Margarita ^a   Sánchez, Esther ^b   Mollejo, Manuela ^b   Piris, Miguel Á ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b HOSPITAL VIRGEN DE LA SALUD   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYCLIN D3; MESSENGER RNA; PROTEIN BCL 6; PROTEIN P27; PROTEIN P53; RNA 18S;

ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; DEREGULATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; LYMPHOID TISSUE; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; ONCOGENE C MYC; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0037327754     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.LAB.0000057000.41585.FD     Document Type: Article

References (55)

1. Artiga MJ, Sáez A, Cristina R, Sánchez-Beato M, Mateo M, Navas C, Mollejo M, and Piris M (2002). A short mutational hot spot in the first intron of BCL-6 is associated with increased BCL-6 expression and with longer overall survival in large B-cell lymphomas. Am J Clin Pathol 160:1371-1380.
2. Bieche I, Franc B, Vidaud D, Vidaud M, and Lidereau R (2001). Analyses of MYC, ERBB2, and CCND1 genes in benign and malignant thyroid follicular cell tumors by realtime polymerase chain reaction. Thyroid 11:147-152.
3. Bieche I, Laurendeau I, Tozlu S, Olivi M, Vidaud D, Lidereau R, and Vidaud M (1999). Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res 59:2759-2765.
4. Bouchard C, Thieke K, Maier A, Saffrich R, Hanley-Hyde J, Ansorge W, Reed S, Sicinski P, Bartek J, and Eilers M (1999). Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J 18:5321-5333.
5. Bradley JF, Rothberg PG, Ladanyi M, and Chaganti RS (1993). Hypermutation of the MYC gene in diffuse large cell lymphomas with translocations involving band 8q24. Genes Chromosom Cancer 7:128-130.
6. Cesarman E, Dalla-Favera R, Bentley D, and Groudine M (1987). Mutations in the first exon are associated with altered transcription of c-myc in Burkitt lymphoma. Science 238: 1272-1275.
7. Chang CC, Liu YC, Cleveland RP, and Perkins SL (2000). Expression of c-Myc and p53 correlates with clinical outcome in diffuse large B-cell lymphomas. Am J Clin Pathol 113:512-518.
8. Christoph F, Schmidt B, Schmitz-Drager BJ, and Schulz WA (1999). Over-expression and amplification of the c-myc gene in human urothelial carcinoma. Int J Cancer 84:169-173.
9. Cigudosa JC, Parsa NZ, Louie DC, Filippa DA, Jhanwar SC, Johansson B, Mitelman F, and Chaganti RS (1999). Cytogenetic analysis of 363 consecutively ascertained diffuse large B-cell lymphomas. Genes Chromosom Cancer 25:123-133.
10. Coller HA, Grandori C, Tamayo P, Colbert T, Lander ES, Eisenman RN, and Golub TR (2000). Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci USA 97:3260-3265.
11. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, and Croce CM (1982). Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 79:7824-7827.
12. Eischen CM, Weber JD, Roussel MF, Sherr CJ, and Cleveland JL (1999). Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 13:2658-2669.
13. Eischen CM, Woo D, Roussel MF, and Cleveland JL (2001). Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis. Mol Cell Biol 21:5063-5070.
14. Felsher DW, Zetterberg A, Zhu J, Tlsty T, and Bishop JM (2000). Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts. Proc Natl Acad Sci USA 97: 10544-10548.
15. Fulda S, Lutz W, Schwab M, and Debatin KM (1999). MycN sensitizes neuroblastoma cells for drug-induced apoptosis. Oncogene 18:1479-1486.
16. Gerbitz A, Mautner J, Geltinger C, Hortnagel K, Christoph B, Asenbauer H, Klobeck G, Polack A, and Bornkamm GW (1999). Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt's lymphoma. Oncogene 18: 1745-1753.
17. Gibson UE, Heid CA, and Williams PM (1996). A novel method for real time quantitative RT-PCR. Genome Res 6:995-1001.
18. Gregory MA and Hann SR (2000). c-Myc proteolysis by the ubiquitin-proteasome pathway: Stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol 20:2423-2435.
19. Greil R, Fasching B, Loidl P, and Huber H (1991). Expression of the c-myc proto-oncogene in multiple myeloma and chronic lymphocytic leukemia: An in situ analysis. Blood 78:180-191.
20. Guo QM, Malek RL, Kim S, Chiao C, He M, Ruffy M, Sanka K, Lee NH, Dang CV, and Liu ET (2000). Identification of c-myc responsive genes using rat cDNA microarray. Cancer Res 60:5922-5928.
21. Heid CA, Stevens J, Livak KJ, and Williams PM (1996). Real time quantitative PCR. Genome Res 6:986-994.
22. Hernandez L, Hernandez S, Bea S, Pinyol M, Ferrer A, Bosch F, Nadal A, Fernandez PL, Palacin A, Montserrat E, and Campo E (1999). c-myc mRNA expression and genomic alterations in mantle cell lymphomas and other nodal nonHodgkin's lymphomas. Leukemia 13:2087-2093.
23. Jack AS, Kerr IB, Evan G, and Lee FD (1986). The distribution of the c-myc oncogene product in malignant lymphomas and various normal tissues as demonstrated by immunocytochemistry. Br J Cancer 53:713-719.
24. Jaffe ES, Harris NL, Stein H, and Vardiman JW. (2001). Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization classification of tumours. Lyon: IARC Press.
25. Ji L, Arcinas M, and Boxer LM (1994). NF-kappa B sites function as positive regulators of expression of the translocated c-myc allele in Burkitt's lymphoma. Mol Cell Biol 14:7967-7974.
26. Kanda K, Hu HM, Zhang L, Grandchamps J, and Boxer LM (2000). NF-kappa B activity is required for the deregulation of c-myc expression by the immunoglobulin heavy chain enhancer. J Biol Chem 275:32338-32346.
27. Khaira P, James CD, and Leffak M (1998). Amplification of the translocated c-myc genes in three Burkitt lymphoma cell lines. Gene 211:101-108.
28. Kramer MH, Hermans J, Wijburg E, Philippo K, Geelen E, van Krieken JH, de Jong D, Maartense E, Schuuring E, and Kluin PM (1998). Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 92:3152-3162.
29. Latil A, Vidaud D, Valeri A, Fournier G, Vidaud M, Lidereau R, Cussenot O, and Biache I (2000). htert expression correlates with MYC over-expression in human prostate cancer. Int J Cancer 89:172-176.
30. Lin Y, Wong K, and Calame K (1997). Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. Science 276:596-599.
31. Loke SL, Neckers LM, Schwab G, and Jaffe ES (1988). c-myc protein in normal tissue. Effects of fixation on its apparent subcellular distribution. Am J Pathol 131:29-37.
32. Madisen L and Groudine M (1994). Identification of a locus control region in the immunoglobulin heavy-chain locus that deregulates c-myc expression in plasmacytoma and Burkitt's lymphoma cells. Genes Dev 8:2212-2226.
33. Nasi S, Ciarapica R, Jucker R, Rosati J, and Soucek L (2001). Making decisions through Myc. FEBS Lett 490:153-162.
34. Neiman PE, Ruddell A, Jasoni C, Loring G, Thomas SJ, Brandvold KA, Lee R, Burnside J, and Delrow J (2001). Analysis of gene expression during myc oncogene-induced lymphomagenesis in the bursa of Fabricius. Proc Natl Acad Sci USA 98:6378-6383.
35. Nesbit CE, Tersak JM, Grove LE, Drzal A, Choi H, and Prochownik EV (2000). Genetic dissection of c-myc apoptotic pathways. Oncogene 19:3200-3212.
36. Nesbit CE, Tersak JM, and Prochownik EV (1999). MYC oncogenes and human neoplastic disease. Oncogene 18: 3004-3016.
37. O'Hagan RC, Ohh M, David G, de Alboran IM, Alt FW, Kaelin WG Jr, and DePinho RA (2000). Myc-enhanced expression of Cull promotes ubiquitin-dependent proteolysis and cell cycle progression. Genes Dev 14:2185-2191.
38. Pagnano KB, Vassallo J, Lorand-Metze I, Costa FF, and Saad ST (2001). p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin's lymphomas. Am J Hematol 67:84-92.
39. Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti RS, Kuppers R, and Dalla-Favera R (2001). Hypermutation of multiple proto-oncogenes in B-cell diffuse largecell lymphomas. Nature 412:341-346.
40. Perez-Roger I, Kim SH, Griffiths B, Sewing A, and Land H (1999). Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27(Kip1) and p21(Cip1). EMBO J 18: 5310-5320.
41. Rao PH, Houldsworth J, Dyomina K, Parsa NZ, Cigudosa JC, Louie DC, Popplewell L, Offit K, Jhanwar SC, and Chaganti RS (1998). Chromosomal and gene amplification in diffuse large B-cell lymphoma. Blood 92:234-240.
42. Saez A, Sanchez E, Sanchez-Beato M, Cruz MA, Chacon I, Munoz E, Camacho FI, Martinez-Montero JC, Mollejo M, Garcia JF, and Piris MA (1999). p27KIP1 is abnormally expressed in diffuse large B-cell lymphomas and is associated with an adverse clinical outcome. Br J Cancer 80:1427-1434.
43. Sanchez-Beato M, Camacho FI, Martinez-Montero JC, Saez AI, Villuendas R, Sanchez-Verde L, Garcia JF, and Piris MA (1999). Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression. p27/KIP1-cyclin D3 colocalization in tumor cells. Blood 94:765-772.
44. Sanchez-Beato M, Saez AI, Navas IC, Algara P, Sol Mateo M, Villuendas R, Camacho F, Sanchez-Aguilera A, Sanchez E, and Piris MA (2001). Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27. Am J Pathol 159:205-213.
45. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, and Lowe SW (1999). INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 13:2670-2677.
46. Schuhmacher M, Kohlhuber F, Holzel M, Kaiser C, Burtscher H, Jarsch M, Bornkamm GW, Laux G, Polack A, Weidle UH, and Eick D (2001). The transcriptional program of a human B cell line in response to Myc. Nucleic Acids Res 29:397-406.
47. Shaffer AL, Rosenwald A, Hurt EM, Giltnane JM, Lam LT, Pickeral OK, and Staudt LM (2001). Signatures of the immune response. Immunity 15:375-385.
48. Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, and Staudt LM (2000). BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 13:199-212.
49. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM, and Kidd VJ (2000). Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 6:529-535.
50. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993). A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994.
51. Villuendas R, Pezzella F, Gatter K, Algara P, Sanchez-Beato M, Martinez P, Martinez JC, Munoz K, Garcia P, Sanchez L, Kocialkowsky S, Campo E, Orradre JL, and Piris MA (1997). p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations. J Pathol 181:51-61.
52. Vitolo U, Gaidano G, Botto B, Volpe G, Audisio E, Bertini M, Calvi R, Freilone R, Novero D, Orsucci L, Pastore C, Capello D, Parvis G, Sacco C, Zagonel V, Carbone A, Mazza U, Palestro G, Saglio G, and Resegotti L (1998). Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: Clinical relevance in 71 patients. Ann Oncol 9:55-61.
53. Wagner AJ, Kokontis JM, and Hay N (1994). Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/ cip1. Genes Dev 8:2817-2830.
54. Wittekindt NE, Hortnagel K, Geltinger C, and Polack A (2000). Activation of c-myc promoter P1 by immunoglobulin kappa gene enhancers in Burkitt lymphoma: Functional characterization of the intron enhancer motifs kappaB, E box 1 and E box 2, and of the 3′ enhancer motif PU. Nucleic Acids Res 28:800-808.
55. Yang W, Shen J, Wu M, Arsura M, FitzGerald M, Suldan Z, Kim DW, Hofmann CS, Pianetti S, Romieu-Mourez R, Freedman LP, and Sonenshein GE (2001). Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene 20:1688-1702.